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Facioscapulohumeral dystrophy (FSHD) is one of
the most common inherited muscular dystrophies.
The causative gene remains controversial and the
mechanism of pathophysiology unknown. Here we
identify genes associated with germline and early
stem cell development as targets of the DUX4 tran-
scription factor, a leading candidate gene for FSHD.
The genes regulated by DUX4 are reliably detected
in FSHD muscle but not in controls, providing direct
support for the model that misexpression of DUX4
is a causal factor for FSHD. Additionally, we show
that DUX4 binds and activates LTR elements from
a class of MaLR endogenous primate retrotranspo-
sons and suppresses the innate immune response
to viral infection, at least in part through the activa-
tion of DEFB103, a human defensin that can inhibit
muscle differentiation. These findings suggest
specificmechanisms of FSHD pathology and identify
candidate biomarkers for disease diagnosis and
progression.
INTRODUCTION
Facioscapulohumeral dystrophy (FSHD) is the third most
common muscular dystrophy. The mutation that causes FSHD
was identified nearly 20 years ago (Wijmenga et al., 1992), yet
the molecular mechanism(s) of the disease remains elusive.
The most prevalent form of FSHD (FSHD1) is caused by the
deletion of a subset of D4Z4 macrosatellite repeats in the
subtelomeric region of chromosome 4q. Unaffected individuals
have 11–100 of the 3.3 kb D4Z4 repeat units, whereas FSHD1
individuals have 10 or fewer repeats. At least one repeat unit
appears necessary for FSHD because no case has been identi-
fied with a complete deletion of D4Z4 repeats (Tupler et al.,38 Developmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier In1996). Each repeat unit contains a copy of the double homeobox
retrogene DUX4 (Clapp et al., 2007; Gabrie¨ls et al., 1999; Lyle
et al., 1995), and inappropriate expression of DUX4 was initially
proposed as a possible cause of FSHD. This was supported
by the observations that repeat contraction is associated with
decreased repressive epigenetic marks in the remaining D4Z4
units (van Overveld et al., 2003; Zeng et al., 2009) and that over-
expression of the DUX4 protein in a variety of cells, including
skeletal muscle, causes apoptotic cell death (Kowaljow et al.,
2007; Wallace et al., 2011; Wuebbles et al., 2010). However,
initial attempts to identify DUX4 mRNA transcripts in FSHD
muscle were unsuccessful, leading to the suggestion that other
genes in the region were causative for FSHD (Gabellini et al.,
2002; Klooster et al., 2009; Laoudj-Chenivesse et al., 2005;
Reed et al., 2007).
Recent progress has returned the focus to theDUX4 retrogene
as a leading candidate for FSHD. First, a subset of individuals
with clinical features of FSHD do not have contracted D4Z4
repeats on chromosome 4 but do have decreased repressive
heterochromatin at the D4Z4 repeats (de Greef et al., 2009)
(FSHD2), indicating that loss of repressive chromatin at D4Z4
is the primary cause of FSHD. Second, genetic studies identified
polymorphisms that create a DUX4 polyadenylation site as
necessary for a D4Z4 contraction to cause FSHD (Lemmers
et al., 2010). Third, high sensitivity RT-PCR assays detect
DUX4 mRNA specifically in FSHD muscle (Dixit et al., 2007;
Snider et al., 2010). Still, a major problem with the hypothesis
that DUX4 expression causes FSHD has been the extremely
low abundance of the mRNA and inability to reliably detect the
protein in FSHD biopsy samples. Our prior work demonstrated
that the low abundance of DUX4 in FSHD muscle cells repre-
sents a relatively high expression in a small subset of nuclei
(Snider et al., 2010). However, it remained unclear whether the
expression of DUX4 in FSHD muscle has a biological conse-
quence that might drive the pathophysiology of FSHD.
The coding sequence of the DUX4 retrogene has been
conserved in primates (Clapp et al., 2007), but whether this
retrogene has a normal physiological function is unknown.
Previously we found that DUX4 is normally expressed at highc.
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repressed in somatic tissues (Snider et al., 2010), whereas the
epigenetic repression of the DUX4 locus in somatic tissues is
less efficient in both FSHD1 and FSHD2, resulting in DUX4
expression in FSHD muscle cell nuclei. The germline-specific
expression pattern of DUX4 is similar to that of other double ho-
meodomain proteins (Booth and Holland, 2007; Wu et al., 2010).
The function of this distinct family of DNA-binding proteins is
unknown, but their shared tissue expression pattern may indi-
cate a possible role for double homeodomain transcription
factors in reproductive biology.
Here we report that DUX4 regulates the expression of genes
involved in germline and early stem cell development. These
DUX4 target genes are aberrantly expressed in FSHD skeletal
muscle but not in control muscle biopsies. Therefore, the low
level of DUX4 expression in FSHD is sufficient to effect numerous
downstream changes and activate genes of germ cell and early
development in postmitotic skeletal muscle. Additionally, we
show that DUX4 binds and activates LTR elements from a class
of MaLR endogenous primate retrotransposons and at the
same time suppresses the innate immune response to retroviral
infection, at least in part through transcriptional activation of
DEFB103, a human defensin that can inhibit muscle differentia-
tion. These findings suggest specific mechanisms of FSHD
pathology and identify candidate biomarkers for disease diag-
nosis and progression.
RESULTS
Identification of Genes Regulated by DUX4 in Human
Primary Myoblasts
Previously, we identified two different DUX4mRNA transcripts in
human skeletal muscle, both at extremely low abundance: a full-
length open reading frame mRNA (DUX4-fl) only detected in
FSHD muscle and an internally spliced form of DUX4 mRNA
(DUX4-s) that maintains the N-terminal double-homeobox
domains but deletes the C-terminal domain and is detected in
both control and FSHDmuscle (Snider et al., 2010). Forced over-
expression of DUX4-fl is toxic to cells, inducing apoptotic cell
death (Kowaljow et al., 2007; Wallace et al., 2011), whereas
forced overexpression of DUX4-s is not toxic to cultured human
skeletal muscle cells (Geng et al., 2011). To determine whether
gene expression is regulated by DUX4-fl and/or DUX4-s in
human muscle cells, we transduced primary myoblasts from
a control individual (unaffected by muscle disease) with a lentivi-
ral vector expressing either DUX4-fl or DUX4-s and performed
expression microarrays. At 24 hr after transduction, DUX4-fl
increased the expression of 1,071 genes and decreased the
expression of 837 genes compared to a control myoblast popu-
lation similarly infected with a GFP expressing lentivirus (2-fold
change and FDR < 0.01); whereas DUX4-s increased the expres-
sion of 159 genes and decreased expression of 45 genes (Fig-
ure 1A; see Table S1 available online for the complete list of
genes regulated by DUX4-fl and/or DUX4-s). Using a slightly
more stringent 3-fold criteria (>1.584 log2-fold change and
FDR < 0.01), 466 genes were increased and 244 decreased by
DUX4-fl; and 37 were increased and one decreased by
DUX4-s. Only two annotated genes were increased 3-fold or
more by both (CCNA1, MAP2), and none were decreasedDeve3-fold or more by both. A representative sample of genes
activated by DUX4-fl is shown in Table 1 and the full set of genes
regulated by DUX4-fl or DUX4-s is in Table S1.
The Gene Ontology (GO) terms significantly enriched in 3-fold
upregulated genes by DUX4-fl included categories such as RNA
polymerase II mediator complexes, RNA splicing and process-
ing, and gamete/spermatogenesis (Table S2A); whereas down-
regulated genes were enriched in immune response pathways
(Table S2B). The upregulation of a large number of transcrip-
tion-related and RNA processing factors suggests that DUX4-fl
might be a central component of a complex gene regulatory
network, and the large number of germline associated genes
suggests a possible role in reproductive biology.
In primary human myoblasts, DUX4-fl robustly induced a large
number of genes not normally detected in skeletal muscle (see
the contrail of genes along the y axis in the left panel of Figure 1A).
These genes are good candidate biomarkers of DUX4 activity in
skeletal muscle, because there is little to no background expres-
sion in control muscle. GO analysis for these highly induced
genes showed enrichment for gamete generation and spermato-
genesis categories (Table S2A). In many cases, DUX4-fl acti-
vated multiple members of gene families involved in germ cell
biology and early development, including some primate-specific
genes (Table 2). We validated the differential expression of 15 of
the DUX4-fl regulated genes by RT-PCR (Figure S1).
Identification of DUX4-fl Binding Sites and a Consensus
Binding Sequence Motif
Double homeodomain proteins comprise a distinct group of
DNA-binding proteins (Holland et al., 2007), but their consensus
recognition sites and genomic targets are unknown. Therefore,
we performed chromatin immunoprecipitation combined with
high throughput sequencing (ChIP-Seq) to identify DUX4-
binding sites in human muscle cells. We used two polyclonal
rabbit antisera against DUX4 (Figures S2A and S2B) to immuno-
precipitate DUX4-fl from human primary myoblasts 24 hr after
transduction with lentiviral expressed DUX4-fl or control non-
transduced primary myoblasts. Nonredundant reads unambigu-
ously mapped to the human genome were computationally
extended to a total length of 200 nucleotides and ‘‘peaks’’
were defined as regions where the number of reads was higher
than a statistical threshold compared to the background (see
Experimental Procedures). Reads mapping to the X and Y chro-
mosomes were excluded from our analysis.
A total of 62,028 and 39,737 peaks were identified at p value
thresholds of 1010 and 1015, respectively, after subtracting
background peaks in the control samples. DUX4-fl peaks were
widely distributed both upstream and downstream of gene tran-
scription start sites (TSSs) with higher numbers in introns and
intergenic regions, but showinga relatively constant peak density
in all genomic regions when normalized for the size of the
genomic compartment (Figure 1B, left). This pattern differs from
that reported for many other transcription factors, such as
MYOD (Cao et al., 2010), shown for comparison (Figure 1B, right),
that show higher average peak density in regions near TSSs.
A de novo motif analysis identified the sequence TAAYB
BAATCA (IUPAC nomenclature) (Figure 1C, top) near the center
of >90% of peaks. To our knowledge, this motif has not been
described for any other transcription factor, but does containlopmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier Inc. 39
Figure 1. DUX4-fl Activates the Expression of Germline Genes and Binds a Double-Homeobox Motif
(A) Pairwise comparison of normalized array data from DUX4-fl versus GFP (left), and DUX4-s versus GFP (right). Blue dots: upregulated genes; red dots:
downregulated genes; blue and red diagonal lines represent 2-fold change. Vertical and horizontal lines represent signal thresholds for calling genes present
or absent.
(B) Gene context of DUX4-fl binding sites (left) or MyoD binding sites (right) represented by peak density, adjusting for prevalence of gene context category in
the genome. Promoter: ±500 bp from the transcription start site (TSS); promoter.pro: ±2 kb from the TSS; prime3: ±500 nt from the end of the transcript; upstream:
2 kb to 10 kb upstream of the TSS; downstream: +2 kb to +10 kb from the end of the transcript; intergenic: >10 kb from any annotated gene.
(C) Top: DUX4-fl motif Logo. The size of each nucleotide at a given position is proportional to the frequency of the nucleotide at that position, and the darkness of
the line connecting two adjacent nucleotides represents corresponding dinucleotide frequency. Bottom: DUX4 binding motif matches MaLR repeat consensus
sequence. We identified the best DUX4 binding sites (bracket) within the MaLR repeats annotated in the RepeatMasker track provided by the UCSC genome
browser (hg18) and extended the motif in the flanking regions to reflect general MaLR repeat consensus.
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tandem and separated by one nucleotide. Approximately 30%
of sequences under the DUX4-fl peaks also contained a second40 Developmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier Inlarger motif that encompasses the primary DUX4-fl binding
motif. This longer motif matches the long terminal repeat (LTR)
of retrotransposons (Figure 1C, bottom). Assessment of thec.
Table 1. Representative Genes Induced by DUX4-fl
Category
Log2
DUX4-fl Fca
Log2
DUX4-s Fca Comments
Germline and stem cells
ZSCAN4 8.3 0.0 Genome stability,
telomere length
PRAMEF1 8.1 0.1 Melanoma antigen family
SPRYD5 8.0 0.1 Expressed in oocyte
KHDC1L 8.0 0.1 KH RNA binding domain
MBD3L2 7.6 0.0 Methyl-CpG-binding protein
TRIM43 5.8 0.0 Preimplantation embryo
TPRX1 4.5 0.1 Homeobox protein
ZNF217 4.1 0.3 Expressed in cancer
stem cells
HSPA2 3.7 0.3 Chaperone, heat
shock 70 Kd
JUP 3.2 0.1 expressed in germline and
testicular cancers
FGFR3 3.1 0.0 Expressed in spermatogonia
SLC2A14 2.4 0.2 Spermatogenesis
ID2 2.3 0.3 Negative regulator of cell
differentiation
PVRL3 2.2 0.4 Spermatid-Sertoli junction
RNA processing
SFRS2B 4.2 0.3 Splicing
THOC4 4.0 0.2 Splicing, RNA transport
ZNHIT6 3.5 0.3 Sno-RNA processing
DBR1 3.4 0.2 RNA lariat debranching
enzyme
TFIP11 3.2 0.1 Spliceosome assembly
CWC15 2.6 0.1 Spliceosome-associated
ARS2 2.6 0.2 miRNA processing
PABPN1 2.6 0.3 PolyA binding
RMRP 2.3 0.1 Mitochondrial RNA
processing
Ubiquitin pathway
SIAH1 3.7 0.1 Targets TRF2 telomere
maintenance
FBXO33 3.2 0.2 E3 ubiquitin-protein
ligase complex
PELI1 2.9 0.1 E3 ligases involved in
innate immunity
USP29 2.6 0.1 Ubiquitin-specific peptidase
ARIH1 2.2 0.8 Ubiquitin-conjugating
enzyme E2 binding protein
TRIM23 2.2 0.6 E3 ubiquitin ligase
involved in immunity
Immunity and innate defense
DEFB103B 6.4 0.1 Innate defense
IFRD1 3.0 0.2 Interferon-related
developmental regulator
CXADR 2.5 0.1 Leukocyte migration
CBARA1 2.1 0.2 T-helper 1-mediated
autoreactivity
Table 1. Continued
Category
Log2
DUX4-fl Fca
Log2
DUX4-s Fca Comments
CXCR4 2.0 0.1 Chemotaxis
General transcription
GTF2F1 3.2 0.3 General transcription
factor IIF
MED26 2.1 0.1 RNA Pol II mediator
complex
RRN3 2.1 0.1 RNA Pol I preinitiation
complex
Cancer expressed
CSAG3 5.9 0.1 Chondrosarcoma-
associated gene
SLC34A2 5.5 0.0 Breast cancer biomarker
PNMA6B 3.6 0.2 Paraneoplastic antigen
Other
FLJ45337 3.7 0.2 Endogenous retrovirus
HNRNPCL1 3.5 0.1 Nucleosome assembly
a Fc = fold change.
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Deverepresentation of DUX4-fl binding at different annotated repeti-
tive elements in the genome shows a nearly 10-fold enrichment
of DUX4-fl binding in the Mammalian apparent LTR-Retrotrans-
poson (MaLR) family of retrotransposons and some enrichment
in the related ERV family (Table S3). Note that the quantitative
estimate of repeat-associated binding sites is conservative
because reads mapping to more than one locus are excluded
from our analysis, which would prevent the identification of
binding sites in highly conserved repetitive regions where reads
are excluded.
MaLR familymembers expanded in the primate lineages (Smit,
1993). Thus, if DUX4-fl binding sites were carried throughout the
genome during this expansion, these newer sites might have
a different sequence motif compared to DUX4-fl binding sites
located outside of MaLR repeats. To determine if the expansion
of MaLR-associated binding sites might obscure the identifica-
tion of a different DUX4 binding motif in nonrepetitive elements,
we performed separate motif analysis of MaLR-associated sites
and sites not associated with repeats; both yielded nearly iden-
tical core motifs, TAAYYBAATCA and TAAYBYAATCA, respec-
tively, but the repeat-associatedmotifs had slightlymore flanking
nucleotides preferences reflecting the LTR sequence (Fig-
ure S2C). Electrophoretic mobility shift assay (EMSA) confirmed
that DUX4-fl binds the core motif present in both MaLR-associ-
ated and nonrepeat associated sites and that mutation of the
core nucleotides abolishes binding (Figures S2D–S2F), including
sites from both repeat and nonrepeat regions. Because the
DUX4-s alternative splice form retains the N-terminal DNA-
binding homeodomains, we hypothesized that it would bind to
the same sites as DUX4-fl. EMSA confirmed that DUX4-s specif-
ically binds the same core binding site as DUX4-fl in vitro (Fig-
ure S2G). Thus, DUX4-s can bind the same sequences as
DUX4-fl but does not activate transcription of the same genes,
which supports the prior determination that the C terminus
contains a transactivation domain (Kawamura-Saito et al., 2006).lopmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier Inc. 41
Table 2. DUX4 Highly Activates Gene Families Involved in Germ
Cell and Early Development
Gene Family Members Biological Context Fca range
Preferentially
expressed in
melanoma
family
PRAMEF1 Cancer-testis
antigen (Chang
et al., 2011)
9–269
PRAMEF2
PRAMEF4-15
PRAMEF17
PRAMEF20
Tripartite
motif-
containing
TRIM43 Testis-expressed,
preimplantation
embryos (Stanghellini
et al., 2009)
27–235
TRIM48
TRIM49
TRIM53
TRIM64
Methyl-binding
protein-like
MBD3L2 Spermatids and germ
cell tumors (Jiang et al.,
2002; Jin et al., 2008)
197–310
MBD3L3
MBD3L5
Zinc finger
and SCAN
domain
containing
ZSCAN4 Telomere maintenance
in embryonic stem cells
(Zalzman et al., 2010)
13–320
ZSCAN5B
ZSCAN5D
Ret-finger
protein-like
RFPL1 Primate neocortex
development
(Bonnefont et al., 2008)
20–336
RFPL1S
RFPL2
RFPL3
RFPL4A
RFPL4B
KH homology
domain
containing
KHDC1 Oocyte- and
embryo-expressed
(Pierre et al., 2007)
108–258
KHDC1L
Family with
sequence
similarity 90
FAM90A1 Primate-specific
gene family with
unknown function
(Bosch et al., 2007)
9–19
FAM90A2P
FAM90A6P
FAM90A7
a Fc = fold change.
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The number of DUX4-fl binding locations exceeds the number of
genes that robustly increase expression in muscle cells following
transduction with DUX4-fl. A genome-wide analysis of peak
height and regional gene expression shows only a weak associ-
ation of binding and gene expression for DUX4-fl (Figure 2A). To
determinewhether DUX4-fl bindingmight function as a transcrip-
tional activator at some of the identified binding sites, DUX4
binding sites from selected genes were cloned upstream of the
SV40 promoter in the pGL3-promoter luciferase construct. Co-
transfection with DUX4-fl in human rhabdomyosarcoma cell
line RD significantly induced luciferase expression independent
of orientation or position, andmutation of the DUX4 bindingmotif
eliminated the induction (Figures 2B and 2C). In contrast to
DUX4-fl, DUX4-s did not activate expression despite demon-
strating in vitro binding to this site (Figure 2B; Figure S2G).
To determine whether DUX4 binding might directly regulate
transcription of select genes, we cloned the 1.9 kb enhancer
and promoter region of the ZSCAN4 gene that includes four
DUX4 binding sites into pGL3-basic reporter vector. Cotransfec-42 Developmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier Intion with DUX4-fl significantly induced expression of this reporter
and mutation of three of the four DUX4 binding sites nearly abol-
ished the induction (Figure 2D, left). DUX4-s interfered with the
activity of DUX4-fl when the two were coexpressed (Figure 2D,
right), suggesting that DUX4-s acts as a dominant negative for
DUX4-fl activity.
DUX4-fl also activated transcription through DUX4 sites in
repetitive elements: DUX4-fl activated transcription of a lucif-
erase reporter containing DUX4 binding sites cloned from
LTRs at a MaLR THE1D element (Figure 2E, left) and RT-PCR
showed induction of endogenous MaLR transcripts in muscle
cells transduced with DUX4-fl (Figure 2E, right).
DUX4-fl Directly Regulates Genes Involved in Germline
Development
To identify the set of genes that might reflect the function of
DUX4-fl prior to the expansion of MaLRs in primates, we identi-
fied the subset of genes activated at least 3-fold by DUX4-fl that
also contain a nonrepeat associated binding site within 6 kb of
the TSS and not separated from the TSS by a binding site for
the insulator factor CTCF (Table S4). The 74 genesmeeting these
criteria are highly enriched for genes involved in stem and germ
cell functions, RNA processing, and regulated components of
the PolII complex, similar to the major GO categories identified
for all of the genes regulated by DUX4-fl. Quantitative RT-PCR
of six DUX4-regulated genes on paired samples of testis
mRNA and skeletal muscle mRNA from two control individuals
found high expression of these targets in the testes and absent,
or nearly absent, expression in skeletal muscle (Figure 3). We
also detected the expression of the related DUXA and DUX1
genes in healthy human testis (data not shown), further support-
ing the notion that this family of double homeodomain proteins
has a role in germ cell biology.
DUX4-fl-Regulated Genes Are Expressed
in FSHD Muscle
To determine whether the low levels of endogenous DUX4-fl
mRNA detected in FSHD skeletal muscle is sufficient to activate
DUX4 target genes, we assessed the expression of these genes
in a set of control and FSHD muscle. Cultured muscle cells from
control biopsies showed low or absent expression of the six
DUX4-fl regulated genes, whereas these genes were expressed
at significantly higher levels in the FSHD muscle cultures
(Figure 4A), including those from both FSHD1 and FSHD2
individuals.
Similar to the expression of DUX4-fl regulated targets in
cultured FSHD muscle, muscle biopsies from FSHD individuals
had readily detectable mRNA of DUX4-fl regulated genes,
although at varying levels in different biopsies (Figure 4B). The
DUX4-fl mRNA is at extremely low abundance in FSHD muscle
and it is notable that some biopsy samples in which the DUX4-fl
mRNA was not detected showed elevation of DUX4 regulated
targets (Table S5; Figure S3A), indicating that the target mRNA
is of significantly higher abundance and perhaps more stable
than the DUX4 mRNA.
To determine whether the expression of these genes in FSHD
muscle cells was directly due to DUX4, we transfected FSHD
muscle cells with siRNA to the endogenous DUX4-fl mRNA.
The siRNA sequences that decreased the DUX4-fl mRNA alsoc.
Figure 2. DUX4-fl Activates Transcription In Vivo and DUX4-s Can Interfere with Its Activity
(A) Comparison of DUX4 binding and regional gene transcription. The DUX4 peak height (y axis, square root transformation) of binding sites located within the
CTCF-flanked domain of the TSS (left) or within ±2 KB of the TSS (right) plotted against the log-2 fold change ofmRNA expression for the gene associated with the
TSS (x axis). The trend line shows a weak association between DUX4 binding and regional gene transcription.
(B) Genomic fragments near theTRIM48 and ZSCAN4 genes containing DUX4 binding sites were cloned into pGL3-promoter reporter vector (schematic, top) and
transfected into human rhabdomyosarcoma cell line RD. Cells were cotransfected with DUX4-fl or DUX4-s. pCS2-b galactosidase (b-gal) was used to balance
DNA amount in control condition. TRIM48mut and ZSCAN4mut, mutated binding sites.
(C) DUX4-fl can act as an enhancer. Left: ZSCAN4 DUX4 binding site in reverse orientation relative to (B) upstream of the SV40 promoter. Right: ZSCAN4 DUX4
binding site in original orientation but moved 30 downstream of the reporter gene. Luciferase activity set relative to control and error bars represent SD of
triplicates.
(D) Left: Genomic fragment upstream of the ZSCAN4 translation start site containing four DUX4 binding sites was cloned into pGL3-basic luciferase vector
(schematic, top). DUX4-fl highly activates the luciferase expression, whereasmutation of the binding sites (ZSCAN4mut) drastically reduces this induction. Right:
Luciferase activity from DUX4-fl is set at 100% (pCS2-b-gal is used to normalize the amount of plasmid). Cotransfection of equal amounts of DUX4-fl and DUX4-s
diminishes luciferase activity.
(E) Left: Genomic fragment from the LTR of THE1D MaLR element containing the DUX4 binding site were cloned into pGL3-promoter vector and tested for
response to DUX4-fl as in (A). Right: Transcripts from endogenous retroelement MaLRs are upregulated by lentiviral transduction of DUX4-fl into primary human
myoblasts. No upregulation is seen with lentiviral transduction of GFP or DUX4-s. Real-time RT-PCR quantitation is reported relative to internal standard RPL13a.
All data represent mean ± SD from at least triplicates.
Developmental Cell
DUX4 Induces Germline Genes in FSHD Muscle
Developmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier Inc. 43
Figure 3. DUX4 Targets Are Normally Expressed in Human Testis but Not in Healthy Skeletal Muscle
DUX4-fl targets expression in human testis versus matched skeletal muscle tissue from two healthy donors. Real-time RT-qPCR analysis of gene expression
is presented relative to internal standard RPL13a and error bars represent SD of PCR triplicates. MYH2 and CKM are markers of skeletal muscle. Qualitative
RT-PCR gel panels are shown below qPCR graphs.
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ure 4C, siRNA 1 and siRNA 4), confirming that endogenous
DUX4 drives the expression of these genes in FSHD muscle
cells. In addition, expression of the dominant negative DUX4-s
(see Figure 2D) also inhibited the endogenous expression of
the target genes (Figure S3B).
DUX4-Induced DEFB103 Inhibits the Innate Immune
Response and Muscle Differentiation
As noted above, genes enriched in the innate immunity pathways
were expressed at lower levels in myoblasts transduced with
lenti-DUX4-fl compared to the lenti-GFP or lenti-DUX4-s (see44 Developmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier InTable S2B). When compared to nontransduced cells, it was
evident that about 350 genes, most of which were in the innate
immunity pathway, were unchanged in the lenti-DUX4-fl trans-
duced myoblasts but increased in cells transduced with either
control lenti-GFP or lenti-DUX4-s (Table S6). Therefore, lentiviral
induction of the innate immune response in human muscle cells
appeared to be inhibited by DUX4-fl. RT-qPCR validated that
lenti-GFP, lenti-DUX4-s, and multiple other lentivirus constructs
induced the innate immune response in myoblasts, whereas
similar titers of lenti-DUX4-fl did not (Figure 5A, left, and data
not shown). Additionally, supernatant fromDUX4-fl infected cells
reduced the induction of these genes by lenti-GFP (Figure 5B),c.
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mediate this suppressive effect.
DUX4-fl robustly induced expression of DEFB103A and
DEFB103B (b-defensin 3) (Figure 5A, right; Table 1; Table S1),
which has been shown to inhibit the transcription of proinflam-
matory genes in TLR4-stimulated macrophages (Semple et al.,
2011). Indeed, addition of DEFB103 peptide also inhibited the
induction of the innate immune response to lenti-GFP when
added to the muscle cells at the time of infection (Figure 5B)
but did not prevent viral entry and transduction as measured
by copies of viral integrants in the genome and levels of GFP
mRNA expressed (data not shown). Thus, DUX4 can prevent
the innate immune response to viral infection in skeletal muscle
cells, at least in part, through the transcriptional induction of
DEFB103.
Like other DUX4-regulated genes, endogenous expression of
DEFB103 was detected in FSHD cultured muscle cells, FSHD
muscle biopsies, and in healthy testes, but little to none was
seen in control skeletal muscle (Figure 5C). DEFB103 has
been previously shown to bind the CCR6, CCR2, and melano-
cortin receptors and to be an antagonist ligand for the CXCR4
receptor, which is important for muscle cell migration and differ-
entiation (Candille et al., 2007; Feng et al., 2006; Jin et al., 2010;
Yang et al., 1999). To determine whether DEFB103 could affect
myoblasts or muscle differentiation, we treated cultured control
human muscle cells with DEFB103 peptide at concentrations
used in anti-microbial and immunological assays (2.5–5.0 ug/
ml) (Funderburg et al., 2007; Midorikawa et al., 2003; Semple
et al., 2011) and assessed changes with gene expression
arrays. Based on a 2-fold change threshold, DEFB103 did not
alter the expression of any genes in myoblasts, although it is
of interest that myostatin was upregulated 50% and RT-
qPCR confirmed that DEFB103 increased the mRNA for
myostatin in myoblasts (Figure 5D). In contrast, exposing
differentiating muscle cells to DEFB103 reduced the expression
of 44 genes relative to the untreated control, the majority of
which were genes associated with muscle differentiation
(Table S7), and RT-qPCR on select genes (ACTA1, CKM,
MYH2, and TNNT3) validated the array results (Figure 5E).
Furthermore, muscle cultures exposed to DEFB103 during
72 hr of differentiation media showed decreased fusion to myo-
tubes and decreased expression of myosin heavy chain,
a marker of terminal muscle differentiation (Figure 5F). There-
fore, DEFB103 activates the expression of myostatin in
myoblasts and inhibits the expression of genes necessary for
normal muscle differentiation, although it remains to be deter-
mined whether this activity is mediated by the CXCR4 receptor.
Therefore, DUX4-mediated expression of DEFB103 in FSHD
muscle can modulate the innate immune response and can
inhibit myogenic differentiation.
DISCUSSION
Recent genetic and molecular studies indicated DUX4 as the
likely candidate gene for FSHD (Dixit et al., 2007; Lemmers
et al., 2010; Snider et al., 2010). Although the abundance of
DUX4-fl mRNA was extremely low in FSHD muscle, we previ-
ously showed that this represented relatively high expression
of both DUX4-fl mRNA and protein in a small percentage ofDevemuscle nuclei at any time point, either because the gene was
on transiently or the expressing nuclei were eliminated (Snider
et al., 2010). Yet, it remained unclear whether DUX4-fl expres-
sion had a biological consequence in FSHD. In our current study,
we identify genes regulated by DUX4-fl and show that they are
expressed at readily detectable levels in FSHD skeletal muscle,
both cell lines and muscle biopsies, but not in control tissues,
providing direct support for the model that misexpression of
DUX4-fl is a causal factor for FSHD. The genes regulated
by DUX4-fl suggest several specific mechanisms for FSHD
pathophysiology.
Many of the genes highly upregulated by DUX4-fl normally
function in the germline and/or early stem cells and are not
present in healthy adult skeletal muscle. This supports a biolog-
ical role for DUX4-fl in germ cell development and suggests
potential diseasemechanisms for FSHD. Activation of the game-
togenic programmight be incompatible with postmitotic skeletal
muscle, leading to apoptosis or cellular dysfunction. Also, the
testis is an immune-privileged site and testis proteins misex-
pressed in cancers can induce an adaptive immune response
(Simpson et al., 2005). In fact, some of the genes regulated by
DUX4-fl, such as the PRAME family (Chang et al., 2011), are
known cancer testis antigens, so it is reasonable to suggest
that expression of these genes in skeletal muscle might also
induce an adaptive immune response. An immune-mediated
mechanism for FSHD is consistent with the focal inflammation
and CD8+ T cell infiltrates that characterize FSHD muscle biop-
sies (Frisullo et al., 2011; Molna´r et al., 1991).
The induction of DEFB103 by DUX4 might influence both the
adaptive and the innate immune response. DEFB103 can have
a proinflammatory role in the adaptive immune response (Fun-
derburg et al., 2007) and can act as a chemo-attractant for
monocytes, lymphocytes, and dendritic cells (Lai and Gallo,
2009). In this regard, it might enhance an adaptive immune
response to germline antigens expressed in FSHD muscle.
Though traditionally known for its role in antimicrobial defense
(Sass et al., 2010), DEFB103 has been shown to suppress the
innate immune response to LPS and TLR4 stimulation in macro-
phages (Semple et al., 2010, 2011), and has also been shown to
be an antagonistic ligand of the CXCR4 receptor (Feng et al.,
2006), which is important for muscle migration, regeneration,
and differentiation (Griffin et al., 2010; Melchionna et al., 2010).
In this study we show that DEFB103 inhibited the innate immune
response to lentiviral infection in skeletal muscle cells, modestly
induced myostatin in myoblasts, and impaired muscle cell
differentiation. Therefore, DEFB103 might contribute to FSHD
pathology by modulating the adaptive and innate immune
response, as well as through inhibiting muscle differentiation.
In this regard it is interesting to note that expression of murine
Defb6 in the skeletal muscle of transgenicmice induced progres-
sive muscle degeneration (Yamaguchi et al., 2007), although the
mechanism was not determined.
Reactivation of retroelements can result in genomic instability
(Belancio et al., 2010) and transcriptional deregulation (Schulz,
2006). Therefore, DUX4 activation of MaLR transcripts might
directly contribute to FSHD pathophysiology. It is interesting
that DUX4 both activates retroelement transcription and sup-
presses the virally induced innate immune response. Although
we have shown that DEFB103 can substitute for DUX4 tolopmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier Inc. 45
Developmental Cell
DUX4 Induces Germline Genes in FSHD Muscle
46 Developmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier Inc.
Developmental Cell
DUX4 Induces Germline Genes in FSHD Musclesuppress the innate immune response, products of retroele-
ments and endogenous retroviruses may do the same and,
thus, the DUX4-mediated suppression of the innate immune
response might be multi-factorial. Because DEFB103 is also
expressed in the testis, it is interesting to consider whether the
role of DUX4 in the germlinemight include a simultaneous activa-
tion of retroelement transcription and suppression of the innate
immune response to those transcripts.
DUX4 regulated targets also include genes involved in RNA
splicing, developmentally regulated components of the Pol II
transcription complex, and ubiquitin-mediated protein degrada-
tion pathways, all of which may have pathophysiological conse-
quences. A recent study indicated that induction of E3 ubiquitin
ligases by DUX4 might cause muscle atrophy in FSHD (Vander-
planck et al., 2011), consistent with our findings that multiple
ubiquitin ligase family members are induced by DUX4. In addi-
tion, myostatin induces some of these ubiquitin ligases in
skeletal muscle (Lokireddy et al., 2011) and it is therefore
possible that both DUX4 induction of ubiquitin ligases and the
modest upregulation of myostatin by DEFB103 that we observed
in this study can both contribute to muscle atrophy. DUX4 is also
known to induce apoptosis in muscle cells and DUX-4 mediated
myopathy in mice has been shown to be p53-dependent
(Wallace et al., 2011). As noted above, the activation of retro-
transposons or reactivation of the gametogenic program, partic-
ularly inducers of cell cycle in postmitotic muscle, might
contribute to apoptosis. In addition, the altered expression of
many factors involved in RNA transcription and splicing might
affect cell differentiation and survival. In many human diseases
a single mutation can effect multiple pathological pathways
that collectively account for the complex disease phenotype.
Our study of DUX4 regulated genes has identified several candi-
date pathways and future work will be necessary to determine
their relative contributions to the disease phenotype.
In this regard, other genes have been identified as candidates
for FSHD. For example, FRG1 expression has been reported to
be elevated in FSHD muscle (Gabellini et al., 2002) and FRG1
transgenic mice display a muscular dystrophy phenotype
(Gabellini et al., 2006). It is interesting that FRG1 is reported to
alter RNA splicing in FSHD muscle (Gabellini et al., 2006) and
that our study shows that DUX4-fl also alters the expression of
many genes that regulate splicing and RNA processing. It will
be important to determine the relative contributions of DUX4
and FRG1 to FSHD pathophysiology; however, the human
genetics shows a convincing linkage to polymorphisms neces-
sary for the polyadenylation of the DUX4 mRNA (Lemmers
et al., 2010), indicating that DUX4 mRNA is a necessary compo-
nent of the disease. Therefore, one therapeutic avenue to pursue
for FSHD is to reduce the activity of DUX4, either by eliminating
its expression in the muscle cells as we have done in vitro withFigure 4. DUX4 Regulated Genes Normally Expressed in the Testis Are
Real-time RT-PCR quantitation of six DUX4-fl target genes, PRAMEF1, RFPL2,
internal standard RPL13a and represent mean ± SD from triplicates. See Table S
(A) Cultured control and FSHD muscle cells. Note, sample 11 is from FSHD2 ind
(B) Control and FSHD muscle biopsies.
(C) Top: RT-PCR gel showing siRNA knockdown of endogenous DUX4-fl in cultur
Negative control siRNA is against unrelated luciferase gene. Bottom: Levels of DU
measured by qPCR. Error bars represent SD of triplicates; *p < 0.05, **p < 0.01
Devean siRNA or by introducing a dominant negative, such as the
DUX4-s splice form.
A previous study identified PITX1 as a DUX4 target gene ex-
pressed in FSHD skeletal muscle and in mouse cells transfected
with DUX4 (Dixit et al., 2007). Others have expressed DUX4 in
mouse muscle cells and identified repression of the glutathione
redox pathway (Bosnakovski et al., 2008). Both of these findings
are consistent with our expression array data. However, because
many of the DUX4 binding sites reside in primate-specificMaLRs
and some of the DUX4 targets are not conserved in mice, further
studies are necessary to determine the conserved and primate-
specific functions of DUX4, an important consideration for
evaluating mouse models of FSHD.
In conclusion, our data support the model that inappropriate
expression of DUX4 plays a causal role in FSHD skeletal muscle
pathophysiology by activating germline gene expression, endog-
enous retrotransposons, and suppressors of differentiation in
skeletal muscle. The set of genes robustly upregulated by DUX4
in FSHD skeletal muscle are candidate biomarkers because
they are absent in control muscle and easily detected in FSHD1
and FSHD2 muscle. Furthermore, some target genes encode
secreted proteins, which offer the potential for developing blood
tests to diagnose FSHD or monitor response to interventions.
Beyond their utilities as candidate biomarkers, the DUX4 targets
identified in this study point to specific mechanisms of disease
and may help guide the development of therapies for FSHD.
EXPERIMENTAL PROCEDURES
Cell Culture
All experiments were performed with approval of the Institutional Review
Boards of the Fred Hutchinson Cancer Research Center and the University
of Rochester. Primary human myoblasts were collected and cultured as
previously described (Snider et al., 2010). Human RD cells were grown in
DMEM in 10% bovine calf serum (Hyclone) and penicillin/streptomycin.
Microarray and GO Analysis
Quadruplicate total RNA samples were collected from control human primary
myoblasts transduced with lentivirus carrying DUX4-fl, DUX4-s or GFP (moi =
15) for 24 hr. Samples were analyzed by Illumina HumanHT-12 v4 Expression
BeadChip Whole Genome arrays. Probe intensities were corrected, normal-
ized, and summarized by the Lumi package of Bioconductor (Du et al.,
2008). Differentially expressed genes were identified by the LIMMA package
of Bioconductor (Wettenhall and Smyth, 2004). Gene set enrichment analysis
(GSEA) was performed using the Bioconductor GOstats package (Falcon and
Gentleman, 2007).
Chromatin Immunoprecipitation and Ultra-High-Throughput
Sequencing
ChIP was performed and ChIP DNA samples were prepared as previously
described (Cao et al., 2010). Anti-DUX4 C terminus rabbit polyclonal anti-
bodies MO488 and MO489 were combined to immunoprecipitate DUX4-fl.
The samples were sequenced with Illumina Genome Analyzer II.Aberrantly Expressed in FSHD Muscle
TRIM43, ZSCAN4, KHDC1, and MBD3L2. Values are expressed as relative to
5 for all sample names and endogenous DUX4-fl expression status.
ividual.
ed FSHDmuscle cells, done in triplicate with Timm17b as an internal standard.
X4-fl target genes relative to the control treated samples were also reduced, as
between DUX4 siRNA and control siRNA treated cells.
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Figure 5. DEFB103 Inhibits Innate Immune Response to Viral Infection and Inhibits Muscle Differentiation
Real time RT-PCR quantitation of innate immune responsive genes and genes involved inmuscle differentiation. Values represent mean ± SD from triplicates and
are either expressed as relative to internal standard RPL13a or as percentage relative to control condition after being normalized to RPL13a.
(A) Expression levels of innate immune responder IFIH1 and secreted factor DEFB103 after infection of muscle cells with lenti-GFP or lenti-DUX4-fl.
(B) Expression levels of innate immune responders IFIH1 and ISG20 after infection with lenti-GFP in the presence of untreated media (control) or media sup-
plemented with human b-defensin 3 peptide (5.0 ug/ml) (DEFB103) or conditioned media from lenti-DUX4-fl (C.M.).
(C) Endogenous expression of DEFB103 in control testis and skeletal muscle tissues (Testis 1/2, Muscle 1/2), FSHDmuscle biopsies (F-Muscle 3/4), and cultured
FSHD and control muscle cells (F-MB and MB).
(D) Upregulation of myostatin (MSTN) in myoblasts cultured in growth media supplemented with 2.5 ug/ml DEFB103.
(E) Expression levels of various muscle marker genes in response to 2.5 ug/ml uM DEFB103 when added to muscle cells cultured in differentiation media. Myf6
and Desmin were included as genes that were unchanged on the arrays.
(F) Cultured human muscle cells in differentiation media for 72 hr either without (Fa and Fb) or with (Fc and Fd) 2.5 mg/ml DEFB103. (Fa and Fc) Phase contrast
showing inhibition of fusion by DEFB103. (Fb and Fd) Myosin heavy chain immunofluorescence (red) and DAPI nuclear stain (blue).
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Sequences were extracted by Illumina package GApipeline and reads were
aligned using BWA to the human genome (hg18). We only kept one of the48 Developmental Cell 22, 38–51, January 17, 2012 ª2012 Elsevier Induplicated sequences to minimize the artifacts of PCR amplification. Reads
mapping to multiple locations in the genome were excluded from our analysis.
Each read was extended in the sequencing orientation to a total of 200 basesc.
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by an in-house developed R package ‘‘peakSig’’ (pending submission to
Bioconductor), which models background reads by a negative binomial distri-
bution. The negative binomial distribution can be viewed as a continuous
mixture of Poisson distribution where the mixing distribution of the Poisson
rate is modeled as a Gamma prior. This prior distribution is used to capture
the variation of background reads density across the genome. Model param-
eters were estimated by fitting the truncated distribution on the number of
bases with low coverage (one to three), to avoid the problem of inferring
effective genome size excluding the nonmappable regions, and to eliminate
contamination of any foreground signals in the high coverage regions. We
also fit a GC dependent mixture model so that the significance of the peaks
is determined not only by peak height, but also by the GC content of the neigh-
boring genomic regions.
Motif Analysis
Weused an in-house developed R package ‘‘motifRG’’ (pending submission to
Bioconductor) described previously for discriminative de novo motif discovery
(Palii et al., 2011). Briefly, it finds motifs that distinguish positive and negative
sequence data sets, which in this study correspond to DUX4 binding sites
and randomly sampled flanking regions of DUX4 binding sites. To generate
a more accurate presentation of the DUX4 binding sites from the consensus
pattern returned by the motifRG package, we further used a positional weight
matrix (PWM) model, using the matches of the consensus pattern as the
seed to initialize the iterative expectation-maximization (EM) refinement
process similar to MEME. The motifs were extended iteratively as long as
there was sequence preference in the flanking region, and refined in the
same EM process.
Luciferase Assay
Transient DNA transfections of RD cells were performed using SuperFect
(QIAGEN) according to manufacturer specifications. Briefly, 3 3 105 cells
were seeded per 35mmplate the day prior to transfection. Cells were cotrans-
fected with pCS2 expression vectors (2 ug/plate) carrying either b-galactosi-
dase, DUX4-fl, or DUX4-s and with pGL3-promoter luciferase reporter vectors
(1 ug/plate) carrying various putative DUX4 binding sites or mutant sites
upstream of the SV40 promoter or pGL3-basic reporter vector (1 mg/plate)
carrying test promoter fragment upstream of the firefly luciferase gene. Cells
were lysed 24 hr posttransfection in Passive Lysis Buffer (Promega). Lucif-
erase activities were quantified using reagents from the Dual-Luciferase
Reporter Assay System (Promega) followingmanufacturer’s instructions. Light
emission was measured using BioTek Synergy2 luminometer. Luciferase data
are given as the averages ± SD of at least triplicates.
Real-Time PCR
One microgram of total RNA was reverse transcribed into first strand cDNA
in a 20 uL reaction using SuperScript III (Invitrogen) and digested with 1 U of
RNase H (Invitrogen) for 20 min at 37C. cDNA was diluted and used for
quantitative PCR with iTaq SYBR Green supermix with ROX (Bio-Rad). The
relative expression levels of target genes were normalized to those of ribo-
somal protein L13A (RPL13A) by 2DCt. Undetermined values were equated to
zero. Standard deviations from the mean of the DCt values were calculated
from triplicates. PCR primers used for detecting the transcripts of the selected
genes are listed in the Supplemental Experimental Procedures. All primers
amplify with similar and high (>90%) efficiencies.
Muscle Biopsies and Human RNA
Muscle biopsy samples were collected at the University of Rochester
Fields Center from the vastus lateralis muscle of clinically affected and
control individuals as previously described (Snider et al., 2010). RNA from
matched tissues from healthy donors were purchased from BioChain
(Hayward, CA).
Statistical Analyses
Statistical significance between two means was determined by unpaired one-
tailed t tests with p value < 0.05. Statistics for the microarray and ChIP-Seq
experiments are described separately.DeveACCESSION NUMBERS
Microarray and ChIP-seq data have been deposited in Gene Expression
Omnibus (GEO) under accession numbers GSE33799 and GSE33838,
respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, seven tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.devcel.2011.11.013.
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